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Novel triacsin C analogs were synthesized and found to be highly effective against rotavirus 
replication at low micromolar or nanomolar concentration ranges with high therapeutic indices in 
cell culture.  
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Abstract  
 
Recently our group has demonstrated that cellular triglycerides (TG) levels play 
an important role in rotavirus replication. In this study, we further examined the roles of 
the key enzymes for TG synthesis (lipogenesis) in the replication of rotaviruses by using 
inhibitors of fatty acid synthase, long chain fatty acid acyl-CoA synthetase (ACSL), and 
diacylglycerol acyltransferase and acyl-CoA:cholesterol acyltransferase in association 
with lipid droplets of which TG is a major component. Triacsin C, a natural ACSL 
inhibitor from Streptomyces aureofaciens, was found to be highly effective against 
rotavirus replication. Thus, novel triacsin C analogs were synthesized and evaluated for 
their efficacies against the replication of rotaviruses in cells. Many of the analogs 
significantly reduced rotavirus replication, and one analog (1e) was highly effective at a 
nanomolar concentration range (ED50 0.1 µM) with a high therapeutic index in cell 
culture. Our results suggest a crucial role of lipid metabolism in rotavirus replication, and 
triacsin C and/or its analogs as potential therapeutic options for rotavirus infections.   
 
Key words: rotavirus; antivirals; triacsin C analogs; lipogenesis  
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1. Introduction  
 
Rotaviruses are non-enveloped, icosahedral viruses with an 11-segment double-
stranded RNA genome  [1]. The capsid of rotavirus is composed of the outer capsid 
proteins, VP4 and VP7, and the major inner capsid protein, VP6. Rotaviruses are 
divided into 7 (A to G) antigenically distinct serogroups based on VP6. Among them, 
group A rotaviruses are the leading cause of severe gastroenteritis in infant and children 
worldwide, associated with over 500,000 death in children younger than 5 years of age 
each year, although attenuated live vaccines are available [1-3].  Majority of rotavirus 
infection-associated mortality occurs in the developing countries. Nonetheless, nearly 1 
in 80 children is hospitalized with rotavirus gastroenteritis by 5 years of age in the US 
[1-3]. Since there are no specific antiviral agent for rotavirus infection, the treatment 
options for rotavirus infection are limited to providing oral rehydration solution to restore 
and maintain hydration until the infection resolves [4]. However, the development of 
rotavirus antivirals to reduce the severity of diseases and duration of rotavirus-related 
hospitalization has been impeded by limited information on the therapeutic targets for 
rotaviruses.  
Previously it was shown that disruption of lipid rafts and/or lipid droplets decrease 
infectious rotaviruses by inhibition of rotavirus morphogenesis [5, 6].  Lipid droplets are 
cellular organelles for storage of neutral fats such as TG and cholesterol ester, and play 
a crucial role in regulating cellular lipid levels. Lipid rafts are microdomains in cell 
membrane enriched in cholesterol, glycosphingolipids, and proteins. These structures 
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are found important for infectious virus particle formation of human hepatitis C virus 
(HCV) [7, 8] and  dengue virus [9], suggesting the importance of lipid homeostasis in 
virus replication. Recently our group has demonstrated that rotavirus replication induced 
an increase in the TG levels in cells, and suppression of increase in TG levels by 
farnesoid X receptor (FXR) agonists significantly inhibited rotavirus replication [10].   
Lipogenesis is the process of producing fats from acetyl-CoA, which is then 
stored as an energy source. During lipogenesis, fatty acid (FA) is synthesized (de novo 
synthesis) from acetyl-CoA, and subsequently esterified with glycerol to form TG. 
Numerous enzymes participate in lipogenesis, which include fatty acid synthase (FASN), 
long chain fatty acid acyl-CoA synthetase (ACSL) 1-6, and diacylglycerol 
acyltransferase (DGAT) 1/2 and Acyl-CoA:cholesterol acyltransferase (ACAT)1/2 [11-
15]. Lipolysis is the reverse pathway of lipogenesis to generate acetyl-CoA and energy 
from TG in which process multiple enzymes including lipases are involved. In this study, 
we found that the commercially available inhibitors for FASN, ACSL, DGAT and ACAT 
significantly reduced the replication of rotaviruses in vitro.  Since triacsin C, a fungal 
metabolite from Streptomyces aureofaciens, is an ACSL inhibitor and showed the most 
potent inhibition on rotavirus replication, we synthesized its analogs and examined their 
antiviral effects against rotavirus. The synthetic sequence is straightforward and efficient 
(Scheme 1 and 2), which would provide flexibility for further optimization. Among the 
triacsin C and its analogs, 1e is the most potent against rotavirus replication with the 
effective dose that reduce 50% of the virus replication (ED50) of 0.1 µM. Our results 
suggest that lipogenic enzymes may represent potential therapeutic targets for rotavirus 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
infection, and triacsin C analogs may be useful as therapeutic options for rotavirus 
infection.  
 
2. Biochemical studies.  
 
The effects of commercially available inhibitors for lipogenesis as well as newly 
synthesized triacsin C analogs (described below) were examined in rotavirus replication 
using SA11 strain in MA104 cells. Various chemical inhibitors including FASN inhibitors 
(cerulenin and C75), ACSL inhibitors (triacsin C and troglitazone), DGAT inhibitors 
(A922500 and betulinic acid), and ACAT inhibitors (CI-976, hexadecylamino-p-amino 
benzoic acid [PHB]) (Figure 1) were obtained from Sigma-Aldrich and Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA).  
 
3. Chemistry  
 
Various triascin C analogs were synthesized from (E,E,E)-2,4,7-undecatrienal (1), which 
was prepared by a modification of the reported procedure [16, 17] (Scheme 1).  Hence, 
bromination of (E)-2-hexen-1-ol (2) with phosphorus tribromide in dichloromethane 
followed by a displacement reaction with 3-(tetrahydropyranyloxy)propynyl magnesium 
bromide and a catalytic amount of copper cyanide afforded enyne 3.  Removal of the 
THP protecting group of 3 with oxalic acid in refluxing methanol followed by selective 
reduction of the propagylic alcohol function with lithium aluminum hydride in diethyl 
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ether gave (E,E)-2,5-nonadien-1-ol (4).  Oxidation of the hydroxyl function of 4 with o-
iodoxybenzoic acid (IBX) in DMSO provided aldehyde 5.  A two-carbon extension 
utilizing the Horner-Wadsworth-Emmons protocol was carried out by the treatment of 
aldehyde 5 with triethyl phosphonacetate and sodium hydride in benzene furnished all-
trans ester 6 in 57% yield.  When THF was used as solvent, under similar reaction 
conditions only (E,E,E)-2,4,6-undecatrienoate (31% yield) was isolated, and 6 was not 
found.  Reduction of ester 6 with lithium aluminum hydride followed by oxidation with 
IBX and DMSO afforded trienal 1 in 82% overall yield (from ester 6).  
Triacsin C analogs including hydrazone derivatives 1a – 1c and 1ba, cyano 
analog 1d, and aminobenzoic acid 1e were synthesized for bio-evaluation. Hydrazone 
formation of 1 with chloromethanesulfonohydrazide, 3-chloropropane-1-
sulfonohydrazide, and propane-2-sulfonohydrazide separately in ethanol at room 
temperature gave hydrazones 1a, 1b, and 1c, respectively, in good to excellent yields 
(Scheme 2). Intramolecular cyclization of 1b with sodium hydride in N,N-
dimethylformamide (DMF) at 25oC gave 1ba.  It should be noted the aforementioned 
hydrazones are stable under silica gel column chromatographic conditions.  Cyano 
compound 1d was obtained from a Horner-Wadsworth-Emmons olefination of aldehyde 
1 with diethyl cyanomethylphosphonate and sodium hydride [18].  Reductive amination 
of aldehyde 1 with 4-aminobenzoic acid in methanol followed by sodium 
cyanoborohydride produced 1e.  Chloromethanesulfonohydrazide, 3-chloropropane-1-
sulfonohydrazide, and propane-2-sulfonohydrazide were prepared by the treatment of 
chloromethanesulfonyl chloride, 3-chloropropane-1-sulfonyl chloride, and propane-2-
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sulfonyl chloride, respectively, with 40% hydrazine (in aqueous solution) in THF at 25oC 
for 2 hrs. After aqueous workup, extraction with diethyl ether, and concentration, the 
crude hydrazine intermediates were used in subsequent steps without purification. It 
should be noted that the synthesis of triacsin C from aldehyde 1 has been reported by 
Tanaka et al. [17]  in less than 0.5% yield from a three-step sequence of reactions. 1e 
not only has a greater bioactivity than triacsin C, its chemical yield is 44% prepared from 
aldehyde 1 in one step. 
 
4. Results and discussion 
 
All inhibitors, cerulenin, C75, triacsin C, troglitazone, A922500, betulinic acid, CI-976 
and PHB, significantly reduced the replication of SA11 rotavirus in cells with ED50 
values of 0.2 - 28.5 µM (Table 1). The ED50 values of cerulenin, C75, A922500, betulinic 
acid and PHB were similar at 11.3 – 28.5 µM, while troglitazone and CI-976 had lower 
ED50 values of 5.8 µM and 4.3 µM, respectively (Table 1). The TD50 of the inhibitors in 
MA104 cells varied at 8.5 – 85.4 µM (Table 1).  Among the tested commercial inhibitors, 
triacsin C was the most effective against rotavirus replication with ED50 of 0.2 µM. The in 
vitro therapeutic index of triacsin C was 248. Similar ED50 values of the inhibitors were 
observed against Wa rotavirus strain, and SA11 strain was used for further studies. 
These results indicate that disruption of lipogenesis induced by rotavirus replication at 
any step significantly inhibited the virus replication.  
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Triacsin C is an analog of polyunsaturated FA, having an 11-carbon alkenyl chain 
with a N-hydroxytriazene moiety at the terminus, and competitively inhibits ACSL 1, 3, 
and 4 [21]. ACSL is a family of enzymes that converts long chain FA to acyl-CoA, which 
serves as a substrate at each cascading step in the synthesis of various lipid molecules 
including TG and cholesteryl ester. In mammals, five isoforms of ACSLs are identified 
(ACSL 1, 3-6) [12]. In lipid droplet-enriched fractions from Huh7 cells, ACSL 3 is the 
most abundant isoform and ACSL 4 is a minor constituent [19]. The role of ACSL3 
seems to be important in the synthesis of neutral lipids in lipid droplets, suggested by 
the finding that the addition of oleic acid as a source of FA in the cells led to the 
accumulation of lipid droplets in association with increased levels of ACSL 3 in lipid 
droplets [20].  
By inhibiting ACSL, triacsin C consequently blocks the synthesis of TG, 
diglycerides, and cholesterol esters [22]. Troglitazone, a member of the 
thiazolidinediones family, is an anti-diabetic and anti-inflammatory drug. It is also known 
to inhibit ACSL4 (but not other ACSL isoforms), and decreased the size of lipid droplets 
in cells [23]. In our study, both triacsin C and troglitazone significantly reduced the 
replication of rotavirus. Furthermore, addition of triacsin C directly to the medium of cell 
culture showed potent antivirus effects against rotavirus replication, suggesting that 
triacsin C readily penetrates the cells.  
Since triacsin C strongly inhibited rotavirus replication, we synthesized various 
analogs of triacsin C, and examined their effects in rotavirus replication and toxicity in 
MA104 cells. The effective synthetic analogs against rotaviruses are shown in Table 1 
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with ED50 and TD50 values, and therapeutic indexes. The analogs have a conserved 11-
carbon chain with various functionalities at the alkylidene-terminal replacing 1,2,3-
triazene of triacsin C. The presence of various sulfonylhydrazones and cyano functions 
(1a-1ba) at the alkylidene-terminal end decreased the antiviral effects compared to 
triazene moiety. However, 1e that contains aminobenzoic acid at the alkylidene-terminal 
end is highly effective in antiviral effects against rotavirus replication with lower ED50 
(0.1 µM) and higher in vitro therapeutic index (285), compared to those of triacsin C. 
Anti-rotaviral effects of triacsin C, 1ba, and 1e were also confirmed with Western blot 
analysis and IFA (Figure 2). The pre-treatment of SA11 rotavirus with triacsin C (100 
µM) or 1e (100 µM) did not affect the viral titer, indicating that the antiviral effects of 
triacsin C and 1e are not the result of direct viral neutralization or virucidal effect on 
rotavirus. The suppression of increase in lipid droplets by triacsin C, 1ba and 1e was 
dose-dependent in Huh-7 cells and was positively correlated (r2 = .89 and .87 for 1ba 
and 1e, respectively) with reduction of rotavirus replication in MA104 cells (Figure 3). 
The results suggest that the inhibition of virus replication by these compounds is 
associated with the suppression of lipid accumulation in the cells triggered by viral 
infection.  
In this study, we demonstrated that rotavirus replication is closely associated with 
lipid metabolism, and inhibition of lipogenic enzymes significantly decreased rotavirus 
replication. We have also synthesized novel triacsin C analogs by modification of the 
alkylidene-terminal end for evaluation of anti-rotavirus activity, and found one of the 
novel analogs, 1e, was highly effective against rotavirus replication. The facile and high-
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yielding synthesis of the analogs would provide flexibility for further optimization. Based 
on these findings, the lipogenic enzymes may serve as potential therapeutic targets for 
rotavirus infection and triacsin C analogs as potential therapeutic options for rotavirus 
infections.   
 
5. Experimental.  
 
5.1 General 
NMR spectra were obtained from a 400-MHz spectrometer (Varian Inc.), in 
CDCl3, unless otherwise indicated, and reported in ppm.  Mass spectra were taken from 
an API 2000-triple quadrupole ESI-MS/MS mass spectrometer (from Applied 
Biosystems). Chemicals and solvents including Chloromethanesulfonyl chloride, 3-
chloropropane-1-sulfonyl chloride, and propane-2-sulfonyl chloride were purchased 
from Fisher Scientific and Aldrich Chemical Co. A modification of the reported 
procedure [16, 17] was used to prepare (E,E,E)-2,4,7-undecatrienal (1), and spectral 
data of all synthetic intermediates including 13C NMR data (which were not reported in 
previous publications [16, 17]) are included herein.   
 
5.2. Representative synthesis 
5.2.1 (E)-1-(2-tetrahydropyranyl)oxy-nona-5-en-2-yne (3). To a solution of 10.0 g (0.1 
mol) of E-2-hexen-1-ol (2) in 100 mL of dichloromethane at -10oC under argon, was 
added 13.5 g (0.05 mol) of PBr3.  After stirring at 25oC for 3 h, the reaction solution was 
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washed with a saturated aqueous solution of NaHCO3 (50 mL), water, and brine, dried 
(MgSO4), concentrated to give 14.5 g (89% yield) of E-1-bromo-2-hexene, which was 
used in the following step without purification.  1H NMR δ 5.8 – 5.65 (m, 2 H, =CH), 3.96 
(d, J = 7 Hz, 2 H), 2.05 (q, J = 7 Hz, 2 H), 1.41 (sextet, J = 7 Hz, 2 H), 0.91 (t, J = 7 Hz, 
3 H); 13C NMR δ 136.7, 126.7, 34.3, 33.9, 22.2, 13.8; MS (electrospray) m/z 165.1 and 
163.1 (M+H+; 100%; bromine isotopes). 
 To a solution of 15 g (0.18 mol) of dihydropyrane and 2 mg of p-toluenesulfonic 
acid was added 10 g (0.18 mol) of 2-propyn-1-ol.  After stirring at 25oC for 3 h, the 
reaction solution was diluted with 100 mL of diethyl ether and washed with 10% 
aqueous NaHCO3, water, and brine, dried (MgSO4), concentrated to give 20.5 g (82% 
yield) of 2-(2-propynyloxy)-tetrahydropyrane. 1H NMR δ 4.83 (t, J = 3.6 Hz, 1 H, CHO), 
4.29 (dd, J = 16, 3 Hz, 1 H, CH2O), 4.26 (dd, J = 16, 3 Hz, 1 H, CH2O), 3.88 – 3.82 (m, 
1 H, CHO), 3.58 – 3.52 (m, 1 H, CHO), 2.42 (d, J = 3 Hz, 1 H, =CH), 1.90 – 1.50 (m, 6 
H); 13C NMR δ 97.0, 79.9, 74.2, 62.1, 54.1, 30.4, 25.5, 19.1; MS (electrospray; negative 
mode) m/z 139.0 (M-H-, 100%).  MS (electrospray; positive mode) m/z 163.1 (M+Na+; 
100%). 
 To a solution of 18 mL (18 mmol) of 1 M ethylmagnesium bromide in THF under 
argon at 0oC, were added 1.7 g (12 mmol) of 2-(2-propynyloxy)-tetrahydropyrane and 4 
mg of CuCN.  After stirring for 0.5 h, 2.0 g (12 mmol) of E-1-bromo-2-hexene was added, 
and the resulting solution was stirred at 25oC for 0.5 hr, neutralized with 0.1 N HCl, and 
extracted with diethyl ether three times.  The combined ether extract was washed with 
water and brine, dried (MgSO4), concentrated, and column chromatographed on silica 
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gel using a mixture of hexane and diethyl ether (20:1) to give 2.0 g  (75% yield) of 
compound 3: 1H NMR δ 5.66 (dt, J = 16, 7 Hz, 1 H, =CH), 5.40 (dt, J = 16, 5.6 Hz, 1 H, 
=CH), 4.83 (t, J = 3 Hz, 1 H, CHO), 4.33 (dt, J = 16, 2.4 Hz, 1 H, CH2O), 4.24 (dd, J = 
16, 2.4 Hz, 1 H, CH2O), 3.89 – 3.82 (m, 1 H, CHO), 3.57 – 3.51 (m, 1 H, CHO), 2.95 (d, 
J = 3.6 Hz, 2 H), 2.00 (q, J = 7 Hz, 2 H), 1.90 – 1.50 (m, 6 H), 1.39 (sextet, J = 7 Hz, 2 
H), 0.90 (t, J = 7 Hz, 3 H); 13C NMR δ 132.5, 124.1, 96.9, 84.4, 77.6, 62.2, 54.9, 34.6, 
30.5, 25.6, 22.6, 22.3, 19.3, 13.9; MS (electrospray) m/z 245.2 (M+Na+; 100%). 
 
5.2.2 (E,E)-2,5-Nanodien-1-ol (4).  A solution of 7.2 g (32 mmol) of compound 3 in 60 
mL of 2% oxalic acid in methanol was heated under reflux for 2 hrs, and most of the 
methanol was removed under a rotary evaporator.  The residue was diluted with diethyl 
ether (100 mL), washed with water and brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a gradient mixture of hexane and diethyl ether as 
eluant to give 3.94 g (88% yield) of E-5-nonen-2-yn-1-ol.  1H NMR δ 5.67 (dt, J = 16, 7 
Hz, 1 H, =CH), 5.39 (dt, J = 16, 5.6 Hz, 1 H, =CH), 4.29 (dt, J = 6, 2 Hz, 2 H, CH2O), 
2.96 (d, J = 2 Hz, 2 H), 2.00 (q, J = 7 Hz, 2 H), 1.39 (sextet, J = 7 Hz, 2 H), 0.90 (t, J = 7 
Hz, 3 H); 13C NMR δ 132.6, 123.9, 84.4, 80.0, 51.7, 34.6, 22.6, 22.2, 13.9; MS 
(electrospray) m/z 161.1 (M+Na+; 100%). 
 To a solution of 5.5 g (40 mmol) of E-5-nonen-2-yn-1-ol in 50 mL of diethyl ether 
under argon was added 1.5 g (39 mmol) of LiAlH4 in portions.  After stirring at 25oC for 
24 h, the reaction mixture was quenched with 50 mL of 1 N NaOH, and extracted with 
diethyl ether three times (50 mL each).  The combined ether extracts were washed with 
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water and brine, dried (MgSO4), concentrated to give 5.0 g (90% yield) of compound 4, 
which was used in the next step without further purification. 1H NMR δ 5.75 – 5.6 (m, 2 
H, =CH), 5.50 – 5.35 (m, 2 H, =CH), 4.12 (t, J = 4 Hz, 2 H, CH2O), 2.75 (t, J = 5 Hz, 2 H), 
1.99 (q, J = 7 Hz, 2 H), 1.38 (sextet, J = 7 Hz, 2 H), 0.89 (t, J = 7 Hz, 3 H); 13C NMR δ 
131.9 (2 C), 129.6, 127.8, 63.9, 35.4, 34.9, 22.8, 22.2, 13.9; MS (electrospray) m/z 
163.1 (M+Na+; 100%). 
 
5.2.3. (E,E)-2,5-Nonadienal (5).  To a solution of 5.0 g (36 mmol) of compound 4 in 13 
mL of DMSO under argon at 25oC was added 12.5 g (45 mmol) of o-iodoxybenzoic acid 
(IBX), and the solution was stirred for 4 h, diluted with diethyl ether (100 mL), and 
washed with water twice (50 mL each).  The aqueous layers were extracted with diethyl 
ether, and the combined ether layers were washed with brine, dried (MgSO4), 
concentrated, and column chromatographed on silica gel using hexane and diethyl 
ether (20:1) as eluant to give 3.45 g (70% yield) of aldehyde 5.  1H NMR δ 9.53 (d, J = 7 
Hz, 1 H, CHO), 6.85 (dt, J = 16, 7 Hz, 1 H, =CH), 6.13 (dd, J = 16, 8 Hz, 1 H, =CH), 
5.55 (dt, J = 15, 5 Hz, 1 H, =CH), 5.43 (dt, J = 15, 5 Hz, 1 H, =CH), 3.03 (t, J = 7 Hz, 2 H, 
CH2), 2.01 (q, J = 7 Hz, 2 H), 1.39 (sextet, J = 7 Hz, 2 H), 0.91 (t, J = 7 Hz, 3 H); 13C 
NMR δ 194.2, 157.3, 134.4, 133.2, 124.6, 35.8, 34.8, 22.6, 13.8; MS (electrospray) m/z 
161.2 (M+Na+; 100%). 
 
5.2.4. Ethyl (E,E,E)-2,4,7-Undecatrienoate (6).  To a mixture of 0.35 g (8.7 mmol) of 
sodium hydride (60% in oil; pre-washed with diethyl ether twice to remove mineral oil) in 
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20 mL of benzene under argon was added 1.95 g (8.7 mmol) of triethyl 
phosphonacetate, and the solution was stirred at 25oC for 2 hrs.  To it, a solution of 1.0 
g (7.2 mmol) of compound 5 in 2 mL of benzene was added via cannula under argon.  
After stirring for 0.5 hr, the reaction solution was neutralized with 0.1 N HCl, and 
extracted twice with diethyl ether.  The combined extract was washed with water and 
brine, dried (MgSO4), concentrated, and column chromatographed on silica gel using 
hexane and diethyl ether (30:1) as eluant to give 0.64 g (57% yield based on recovered 
starting material) of compound 6 and 0.25 g (25% recovery) of compound aldehyde 5.  
1H NMR δ 7.27 (dd, J = 16, 10 Hz, 1 H, =CH), 6.22 – 6.09 (m, 2 H, =CH), 5.80 (d, J = 16 
Hz, 1 H, =CH), 5.52 – 5.37 (m, 2 H, =CH), 4.20 (q, J = 7 Hz, 2 H), 2.86 (t, J = 6 Hz, 2 H, 
CH2), 1.99 (q, J = 7 Hz, 2 H), 1.39 (sextet, J = 7 Hz, 2 H), 1.30 (t, J = 7 Hz, 3 H), 0.90 (t, 
J = 7 Hz, 3 H); 13C NMR δ 167.5, 145.0, 142.8, 132.9, 128.8, 126.5, 119.8, 60.4, 36.1, 
34.9, 22.7, 14.5, 13.9; MS (electrospray) m/z 231.0 and 163.1 (M+Na+; 100%), 209.2 
(M+H+). 
 
5.2.5. (E,E,E)-2,4,7-Undecatrienal (1).  To a solution of 0.63 g (3.0 mmol) of compound 
6 in 20 mL of diethyl ether under argon at 0oC was added 0.12 g (3.0 mmol) of LiAlH4, 
and the solution was stirred for 1 hr, diluted with water carefully, and extracted with 
diethyl ether twice. The combined extracts were washed with water and brine, dried 
(MgSO4), and concentrated to give 0.43 g (85% yield) of (E,E,E)-2,4,7-undecan-1-ol.  1H 
NMR δ 6.23 (dd, J = 15, 11 Hz, 1 H, =CH), 6.05 (dd, J = 15, 11 Hz, 1 H, =CH), 5.78 – 
5.67 (m, 2 H, =CH), 5.47 – 5.37 (m, 2 H, =CH), 4.16 (q, J = 6 Hz, 2 H, CHO), 2.78 (t, J = 
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6 Hz, 2 H, CH2), 1.98 (q, J = 7 Hz, 2 H), 1.37 (sextet, J = 7 Hz, 2 H), 0.89 (t, J = 7 Hz, 3 
H); 13C NMR δ 134.1 (2 C), 132.1, 130.1 (2 C), 129.9, 127.7, 63.7, 35.8, 34.9, 22.8, 
13.9; MS (electrospray) m/z 205.1 (M+K+; 100%), 189.1 (M+Na+). 
 To a solution of 0.43 g (2.6 mmol) of (E,E,E)-2,4,7-undecan-1-ol in 3 mL of 
DMSO under argo was added 0.91 g (3.3 mmol) of IBX, and the solution was stirred at 
25oC for 4 h, diluted with dichloromethane (50 mL), and washed with water (50 mL).  
The aqueous layer was extracted with dichloromethane, and the combined organic 
layers were washed with brine (20 mL), dried (MgSO4), concentrated, and column 
chromatographed on silica gel using hexane and diethyl ether (20:1) as eluant to give 
0.41 g (96% yield) of aldehyde 1.  1H NMR δ 9.55 (d, J = 8 Hz, 1 H, CHO), 7.10 (dd, J = 
15, 9 Hz, 1 H, =CH), 6.37 – 6.24 (m, 2 H, =CH), 6.10 (dd, J = 15, 7.6 Hz, 1 H, =CH), 
5.55 – 5.38 (m, 2 H, =CH), 2.91 (t, J = 9.6 Hz, 2 H, CH2), 2.01 (q, J = 7 Hz, 2 H), 1.40 
(sextet, J = 7 Hz, 2 H), 0.91 (t, J = 7 Hz, 3 H); 13C NMR δ 194.1, 152.8, 145.4, 133.4, 
130.6, 129.0, 126.0, 36.3, 34.9, 22.7, 13.9; MS (electrospray) m/z 187.1 (M+Na+, 100%). 
 
5.2.6. (E)-chloro-N'-((2E,4E,7E)-undeca-2,4,7-trienylidene)methanesulfonohydrazide 
(1a).    A solution of 20 mg (0.12 mmol) of (E,E,E)-2,4,7-undecatrienal (1) and 35 mg 
(0.24 mmol) of chloromethanesulfonohydrazide in 1 mL of ethanol was stirred under 
argon at 25oC for 2 hrs, and ethanol was removed under a rotary evaporator.  The 
residue was diluted with 20 mL of diethyl ether, washed with water (15 mL) three times, 
and brine (15 mL).  The organic layer was dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a 1:1 mixture of hexane and diethyl ether as eluent 
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to give 35 mg (100% yield) of 1a:  1H NMR (CDCl3) δ 7.91 (s, 1 H, NH), 7.55 (d, J = 10 
Hz, 1 H, N=CH), 6.56 (dd, J = 15, 10 Hz, 1 H), 6.27 – 6.15 (m, 2 H), 5.97 (dt, J = 12, 7 
Hz, 1 H), 5.47 – 5.38 (m, 2 H), 4.70 (s, 2 H, CH2Cl), 2.85 (t, J = 7 Hz, 2 H), 1.99 (q, J = 7 
Hz, 2 H), 1.39 (sextet, J = 7 Hz, 2 H), 0.90 (t, J = 7 Hz, 3 H);  13C NMR (CDCl3) δ 152.0, 
142.3, 140.0, 132.8, 129.7, 126.7, 125.3, 53.0, 36.1, 34.9, 22.7, 13.9;  MS 
(electrospray) m/z 313.0 (M+Na+; 100%). 
 
5.2.7.(E)-3-chloro-N'-((2E,4E,7E)-undeca-2,4,7-trienylidene)propane-1-sulfonohydrazide 
(1b).  A similar procedure to that described above was followed. From 20 mg (0.12 
mmol) of aldehyde 1 and 42 mg (0.24 mmol) of 40% hydrazine, 38 mg (98% yield) of 1b 
was obtained after column chromatographic purification.  1H NMR (CDCl3) δ 8.08 (s, 1 H, 
NH), 7.49 (d, J = 10 Hz, 1 H, N=CH), 6.52 (dd, J = 15, 10 Hz, 1 H), 6.27 – 6.14 (m, 2 H), 
5.94 (dt, J = 12, 7 Hz, 1 H), 5.49 – 5.38 (m, 2 H), 3.68 (t, J = 7 Hz, 2 H, CH2Cl), 3.43 (dd, 
J = 7, 3 Hz, 2 H, CH2S), 2.84 (t, J = 7 Hz, 2 H), 2.31 (pentet, J = 7 Hz, 2 H), 1.99 (q, J = 
7 Hz, 2 H), 1.37 (sextet, J = 7 Hz, 2 H), 0.89 (t, J = 7 Hz, 3 H);  13C NMR (CDCl3) δ 
150.4, 141.3, 139.2, 132.7, 129.8, 126.9, 125.7, 48.8, 42.8, 36.0, 34.9, 26.7, 22.7, 13.9;  
MS (electrospray) m/z 341.0 (M+Na+; 100%). 
 
5.2.8. (E)-N'-[(2E,4E,7E)-Undeca-2,4,7-trienylidene]propane-2-sulfonohydrazide (1c).  
Following a similar reaction sequence as that described for 1a, from 25 mg (0.15 mmol) 
of aldehyde 1 and 42 mg (0.31 mmol) of propane-2-sulfonohydrazide, gave 32 mg (74% 
yield) of 1c.  1H NMR (CDCl3) δ 7.90 (s, 1 H, NH), 7.48 (d, J = 10 Hz, 1 H, N=CH), 6.50 
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(dd, J = 15, 10 Hz, 1 H), 6.24 (dd, J = 15, 10 Hz, 1 H), 6.16 (dd, J = 14, 10 Hz, 1 H), 
5.92 (dt, J = 15, 7 Hz, 1 H), 5.46 – 5.37 (m, 2 H), 3.53 (heptet, J = 7 Hz, 1 H, CH), 2.83 
(t, J = 7 Hz, 2 H), 1.99 (q, J = 7 Hz, 2 H), 1.41 (d, J = 7 Hz, 6 H), 1.38 (sextet, J = 7 Hz, 
2 H), 0.89 (t, J = 7 Hz, 3 H);  13C NMR (CDCl3) δ 149.4, 140.6, 138.8, 132.6, 129.9, 
126.9, 126.0, 52.4, 36.0, 34.9, 22.7, 16.4, 13.9;  MS (electrospray) m/z 307.1 (M+Na+; 
100%). 
 
5.2.9. (2E,4E,6E,9E)-Trideca-2,4,6,9-tetraenenitrile (1d). To a mixture of 15 mg (0.36 
mmol) of sodium hydride (washed twice with distilled anhydrous diethyl ether) in 1 mL of 
benzene under argon was added 64 mg (0.36 mmol) of diethyl 
cyanomethylphosphonate, and the solution was stirred at 25oC for 2 hrs. To it, a 
solution of 40 mg (0.24 mmol) of aldehyde 1 in 1 mL of benzene was added via syringe.  
The resulting solution was stirred for 1 hour, diluted with water (10 mL), neutralized with 
0.1 N HCl solution, and extracted with diethyl ether three times (20 mL each).  The 
combined extract was washed with brine, dried (MgSO4), concentrated, and column 
chromatographed on silica gel using a 30:1 mixture of hexane and diethyl ether as 
eluant to give 26 mg (58% yield) of 1d.  1H NMR (CDCl3) δ 7.00 (dd, J = 15, 10 Hz, 1 H), 
6.52 (dd, J = 15, 10 Hz, 1 H), 6.22 – 6.05 (m, 2 H), 6.00 (dt, J = 15, 7 Hz, 1 H), 5.46 – 
5.38 (m, 2 H), 5.28 (d, J = 15 Hz, 1 H), 2.86 (t, J = 7 Hz, 2 H), 1.99 (q, J = 7 Hz, 2 H), 
1.39 (sextet, J = 7 Hz, 2 H), 0.90 (t, J = 7 Hz, 3 H); 13C NMR (CDCl3) δ 150.6, 142.0, 
140.7, 132.8, 129.7, 127.5, 126.7, 195.0, 97.2, 36.1, 34.9, 22.7, 13.9; MS (electrospray) 
m/z 210.1 (M+Na+; 100%). 
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5.2.10. 2-[(2E,4E,7E)-Undeca-2,4,7-trienylideneamino]-1,1-dioxo-1-isothiazolidine (1ba).  
A solution of 15 mg (47 µmol) of 1b and 2.0 mg (50 µmol) of sodium hydride in 0.5 mL 
of DMF (distilled) under argon was stirred at 25oC for 3 days.  The resulting solution was 
neutralized with diluted aqueous HCl solution, and extracted with diethyl ether twice (25 
mL each).  The combined extract was washed with water three times (20 mL each), and 
brine (20 mL), dried (MgSO4), concentrated, and column chromatographed on silica gel 
using a 1:1 mixture of hexane and diethyl ether as eluant to give 6 mg (46% yield) of 
1ba.  1H NMR (CDCl3) δ 7.54 (d, J = 10 Hz, 1 H, N=CH), 6.54 (dd, J = 15, 10 Hz, 1 H), 
6.32 (dd, J = 15, 10 Hz, 1 H), 6.18 (dd, J = 15, 10 Hz, 1 H), 5.91 (dt, J = 15, 7 Hz, 1 H), 
5.46 – 5.40 (m, 2 H), 3.59 (t, J = 7 Hz, 2 H), 3.22 (t, J = 7 Hz, 2 H), 2.84 (t, J = 7 Hz, 2 
H), 2.49 (pentet, J = 7 Hz, 2 H), 1.99 (q, J = 7 Hz, 2 H), 1.38 (sextet, J = 7 Hz, 2 H), 0.89 
(t, J = 7 Hz, 3 H);  13C NMR (CDCl3) δ 151.5, 140.8, 138.6 (2 C), 132.6, 130.1, 126.8, 
46.3, 45.3, 36.1, 34.9, 30.6, 22.8, 18.0, 13.9;  MS (electrospray) m/z 305.2 (M+Na+; 
100%). 
 
5.2.11. 4-((2E,4E,7E)-Undeca-2,4,7-trienylamino)benzoic acid (1e).  A solution of 30 mg 
(0.18 mmol) of aldehyde 1 and 24 mg (0.18 mmol) of 4-aminobenzoic acid in 5 mL of 
methanol was stirred under argon at 25oC for 1 hr.  To it, 10 µL of acetic acid and 30 mg 
(0.48 mmol) of sodium cyanoborohydride were added sequentially.  After stirring at 
25oC for 12 hrs, the reaction solution was diluted with aqueous ammonium chloride, and 
extracted with diethyl ether twice (25 mL each).  The combined extract was washed with 
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brine, dried (MgSO4), concentrated and column chromatographed on silica gel using a 
gradient mixture of hexane and ethyl acetate as eluant to give 23 mg (44% yield) of 1e.  
1H NMR (CDCl3) δ 7.93 (d, J = 8 Hz, 2 H, Ar), 6.58 (d, J = 8 Hz, 2 H, Ar), 6.25 (dd, J = 
15, 10 Hz, 1 H), 6.06 (dd, J = 15, 10 Hz, 1 H), 5.75 – 5.64 (m, 2 H), 5.45 – 5.40 (m, 2 H), 
3.86 (d, J = 7 Hz, 2 H, CH2H), 2.78 (t, J = 7 Hz, 2 H), 1.98 (q, J = 7 Hz, 2 H), 1.38 
(sextet, J = 7 Hz, 2 H), 0.90 (t, J = 7 Hz, 3 H);  13C NMR (CDCl3) δ 171.8, 152.6, 134.0, 
132.9, 132.5, 132.1, 129.7, 127.6, 127.1, 117.6, 111.9, 45.3, 35.8, 34.9, 22.8, 13.9; MS 
(electrospray) m/z 308.1 (M+Na+; 100%). 
 
6. Biochemical studies. 
 
6.1. Cells, antisera and reagents. The MA104 cell line was maintained in minimum 
essential medium (MEM) containing 5% fetal bovine serum and antibiotics (penicillin 
and streptomycin). Antibodies specific to rotavirus VP6 or β-actin were obtained from 
Santa Cruz Biotechnology Inc. Rotavirus strains including Wa (human G1) and SA11 
(primate G3) were obtained from American Type Culture Collection (ATCC, Manassas, 
VA).  
 
6.2. Nonspecific cytotoxic effects. Confluent MA104 grown in 24-well plates were 
treated with various concentrations of each compound for 24 hrs. Cell cytotoxicity was 
measured by a CytoTox 96® non-radioactive cytotoxicity assay kit (Promega, Madison, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
20 
 
WI), and TD50 value of each compound was determined using the method of Litchfield 
and Wilcoxon [24]. 
 
6.3. Rotavirus infection and treatments in cell culture. Fully confluent monolayered 
MA104 cells grown in 6- or 12-well plates were inoculated with Wa or SA11 rotavirus at 
high (2) or low (0.01) multiplicity of infection (MOI) for 1 hr. Following washing step with 
phosphate buffered saline (PBS), MEM containing each compound or DMSO (0.1%) 
was added to each well. In addition, trypsin (Sigma-Aldrich) was included at 1 µg/ml in 
medium for rotavirus replication. The concentrations of each compound in the cells were 
less than 50 µM for cerulenin, C75, triacsin C, various triacsin C analogs, A922500 and 
PHB, and less than 20 µM for betulinic acid, and CI-976. As a control, nitazoxanide was 
used at 0.5 to 5 µM. Virus replication was monitored at 12, 24 and 48 hr post infection 
by immunofluorescent assay (IFA) or Western blot analysis with antibody against VP6, 
and the 50% tissue culture infectious dose (TCID50)/ml was also determined. The ED50 
was calculated based on TCID50  titers at 24 hr post infection (with 0.05 MOI) for each 
compound using the method of Litchfield and Wilcoxon [24]. 
 
6.4. Pre-treatment of viruses with triacsin C or 1e. To investigate if triacsin C or its 
analog 1e has virucidal effects on rotavirus, SA11 rotavirus of high titer (> 109 
TCID50/ml) was pre-incubated with PBS (or DMSO), triacsin C (200 µM) or 1e (200 µM) 
at 37 °C for 2 hrs. Then the mixture was diluted up  to 100 times for cell inoculation. 
Virus infected cells were incubated with medium containing trypsin for up to 24 or 48 hrs, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
and the virus replication was monitored by the titration of progeny viruses using the 
TCID50 method. 
 
6.5. Determination of viral replication using IFA, Western blot analysis and TCID50 
method.  Virus replication in cell culture was assessed by the IFA or Western blot 
analysis at 12 or 24 hr post infection before the extensive cytopathic effects (CPE) are 
induced by viral infection. Viral replication was also titrated with the TCID50 method at 
24 and 48 hr post infection after cells were lysed with repeated freezing and thawing. 
IFA: cells were fixed with 100% methanol at room temperature for 30 min. Then, 
monoclonal antibody specific for rotavirus VP6 was applied to the cells followed by goat 
anti-mouse IgG conjugated fluorescein isothiocyanate (FITC). The stained cells were 
observed under a fluorescence microscope. Western blot analysis: The expression 
levels of VP6 in the presence of each compound were also assessed by Western blot 
analysis. The cells were lysed at 12 hr post infection, and the cell lysates were prepared 
in SDS-PAGE sample buffer containing 1% β-mercaptoethanol, and sonicated for 20 
sec. The proteins were resolved in a 10% Novex Tris-Bis gel (Invitrogen) and 
transferred to a nitrocellulose membrane. The membranes were probed with 
monoclonal antibody specific for rotavirus VP6, and the binding of the antibodies was 
detected with peroxidase-conjugated goat anti-mouse IgG. In addition, separate 
membranes were probed with antiserum specific for β-actin, and appropriate 
peroxidase-conjugated secondary antibodies were used. Following incubation with a 
chemiluminescent substrate (Pierce Biotechnology, Rockford, IL), signals were detected 
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on X-ray film. TCID50 method: A standard TCID50 method with the 10-fold dilution of 
each sample was used for virus titration in MA104 cells according to the Reed and 
Muench method [25].  
 
6.6. Lipid staining of cells in the absence or presence of rotavirus infection.  Confluent 
MA104 cells in 96-well plates were infected with mock-medium or SA11 rotavirus at a 
MOI of 10. Virus infected cells were treated with various concentrations of mock (DMSO, 
0.1%), cerulenin, C75, triacsin C, 1e, A922500, betulinic acid, I-976 or PHB, and 
incubated with medium with NBD-cholesterol (1 µg/ml) and trypsin (1 µg/ml). NBD-
cholesterol rapidly distributes in the cells and targets lipid droplets by binding 
specifically to lipid droplet-specific protein with high affinity [26]. At 10 hr after virus 
infection, cells were fixed with 4% formaldehyde for 10 min, followed by washing with 
PBS twice. Then the fluorescence signals from NBD-cholesterol in the cells were 
observed under a fluorescent microscope.   
In human liver carcinoma Huh-7 cells, lipid droplets develop spontaneously in cell 
culture [27]. In separate experiments, confluent Huh-7 cells in opaque 96-well plates 
were treated with various concentrations of mock (DMSO, 0.1%), cerulenin, C75, 
triacsin C, 1e, A922500, betulinic acid, CI-976, or PHB and incubated for 72 hrs. After 
72 hr, the medium containing NBD-cholesterol (1 µg/ml) was replaced and cells were 
further incubated for 12 hrs. Then cells were fixed with 4% formaldehyde for 10 min, 
and washed with PBS. The fluorescence signals of the cells were observed under a 
fluorescent microscope.  
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Table 1. The effects of the inhibitors of lipogenic enzymes and triacsin C analogs in the 
replication of rotavirus   
a  Each ED50 and TD50 value was the averge of at least 3 independent tests.  
 Rotavirus (SA11)  Class 
Inhibitors ED50 (µM)a TD50(µM) 
FASN Cerulenin 28.5 56.7 
 C75 21.2 28.5 
ACSL Triacsin C 0.2 49.6 
 Troglitazone 5.8 18.5 
DGAT A922500 23.2 85.4 
 Betulinic acid 22.5 27.8 
ACAT CI-976 4.3 8.5 
 PHB 11.3 75.5 
Triacsin C  1a 8.7 74.0 
analogs 1b 11.5 86.3 
 1c 9.8 90.2 
 1d 21.3 78.8 
 1ba 2.2 86.4 
 1e 0.1  28.5 
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Scheme 1 
 
Scheme 1.  Preparation of 2,4,7-undeca-trienal (1)
2
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Scheme 2 
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Scheme 2.  Syntheses of Triacsin C Analogs
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Figure legends  
 
Figure 1. Structures of inhibitors specific for FASN, ACSL, DGAT and ACAT. 
 
Figure 2. The effects of triacsin C, and its analogs in rotavirus (SA11) replication 
determined by Western blot analysis (A) and IFA  (B).  SA11 rotavirus was inoculated to 
the cells at a MOI of 2, and cells were incubated with or without each inhibitor (triacsin C, 
1e or 1ba). Cell lysates were collected at 12 hr post infection (A) and virus infected cells 
were fixed at 12 hr post infection (B) at the indicated concentrations.  
 
Figure 3. Lipid droplets monitored with NDB-cholesterol in rotavirus (SA11) infected 
MA104 cells (A) or uninfected Huh-7 cells (B). A. Lipid droplets in MA104 cells infected 
with SA11 rotavirus with a MOI of 10. Panels, a and b: cells incubated with mock-
medium (a) or SA11 rotavirus (b) for 10 hr. Panels, c and d: SA11 rotavirus infected 
cells incubated in the presence of triacsin C (1 µM) (c) or 1e (1 µM) (d) for 10 hr. B. The 
development of lipid droplets in Huh-7 cells incubated with mock-medium, triacsin C, or 
1e. Panel a: 1 day old cells; b: 4 day old cells; c and d: 4 day old cells incubated in the 
presence of triacsin C (1 µM)(c) or 1e (1 µM)(d).  
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Highlights  
 
>  Rotaviral diarrheal remained as one of the most important causes for mortality worldwide. > 
there is no specific antiviral drug for rotavirus infection. > Triacsin C, a fungal metabolite, was 
found to be highly effective against rotavirus replication. > One triacsin C analog, TC20, was 
highly effective in a nanomolar concentration range with a high therapeutic index. > Triacsin C 
and/or its analogs are potential therapeutic options for rotavirus infections.   
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